Metagenomi, a precision genetic medicines company committed to developing curative therapeutics for patients by leveraging its metagenomics-derived genome editing toolbox, named Pamela Wapnick, MBA, as Chief Financial Officer.
Pamela Wapnick has more than 20 years of diversified financial leadership experience spanning strategic and operational finance roles. Prior to joining Metagenomi, Pamela served as Chief Financial Officer at several biotech and medical technology companies including Diality, Capsida Biotherapeutics, and Graybug Vision, where she built the finance functions and led financial planning and strategy. As Chief Financial Officer at True North Therapeutics, Pamela completed preparations for an initial public offering before the company’s acquisition by Bioverativ. Prior to that, she served in various executive leadership roles at Amgen, including Corporate Treasurer and Vice President R&D Finance, where she was responsible for a $3 billion global R&D budget focused on advancing research and pipeline programs.
Pamela holds an MBA from Columbia University and a BA in Economics from Wellesley College.
Partners

- Ellen Travers
- 908-358-8094
- /ellen-travers-1950183

- Sara S. Hagar
- 610-407-4663
- /sarahagar

- Amy Bottoms
- 360-710-1491
- /amy-bottoms